Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-3242 + Lenacapavir vs Biktarvy in Treatment-Naive People With HIV-1
NCT07708727Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2026
- Primary completion
- Oct 2030
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of GS-3242 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at 52 weeks. Started Jul 2026; status: recruiting.
02
Drugs
GS-3242
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07708727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708727.